Table 4.
Change in advanced lipoprotein characterization, glucose metabolism, and inflammation between baseline and Week 12, by treatment group during RCT period
Adalimumab vs Placebo1 | Phototherapy vs Placebo1 | F-test p2 | |
---|---|---|---|
TC | 6.481 (0.386) | 8.154 (0.280) | 0.514 |
Efflux | 0.046 (0.357) | 0.035 (0.496) | 0.629 |
LDL-P | 9.193 (0.897) | 52.320 (0.467) | 0.743 |
HDL-P | 2.558 (0.089) | 3.319 (0.030) | 0.071 |
Log Insulin | 0.014 (0.934) | 0.071 (0.679) | 0.909 |
Log Adiponectin | −0.142 (0.672) | −0.151 (0.655) | 0.879 |
Log Leptin | −0.086 (0.504) | 0.050 (0.695) | 0.568 |
Log CRP | −0.883 (0.002) | −0.752 (0.009) | 0.004 |
Log TNF-alpha | −0.411 (<0.001) | −0.177 (0.065) | <0.001 |
Log IL6 | −0.764 (0.007) | −0.683 (0.019) | 0.014 |
GlycA | −41.165 (0.006) | −7.199 (0.628) | 0.015 |
Difference of differences (statistically significant findings bolded)
Global difference (statistically significant findings bolded)